{{Drugbox
| IUPAC_name = ''N''-[(4-amino-2-methylpyrimidin-5-yl)methyl]-''N''-[(1''E'')-4-hydroxy-1-methyl-2-(propyldisulfanyl)but-1-en-1-yl]formamide
| image = Prosultiamine.png
| alt = Skeletal formula of prosultiamine
| width = 240
| image2 = Prosultiamine 3D ball.png
| alt2 = Ball-and-stick model of the prosultiamine molecule
| width2 = 260

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|prosultiamine}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = [[Mouth|Oral]]

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 59-58-5
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 5355019
| ChemSpiderID = 4511078
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = UI32MM3XE3

<!--Chemical data-->
| C=15 | H=24 | N=4 | O=2 | S=2 
| molecular_weight = 356.51 g/mol
| smiles = O=CN(\C(=C(\SSCCC)CCO)C)Cc1cnc(nc1N)C
}}

'''Prosultiamine''' ('''Alinamin''', '''Binova''', '''Jubedel''', '''Taketron''', '''Thiobeta''', '''Thiotiamina'''), also known as '''thiamine propyl disulfide''' ('''TPD'''), is a [[disulfide]] [[thiamine]] derivative developed in [[Japan]] in the 1950s as a treatment for [[Thiamine#Deficiency|vitamin B<sub>1</sub> deficiency]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = | isbn = 3-88763-075-0 | oclc = | doi = | accessdate = }}</ref><ref name="isbn0-412-46630-9">{{cite book | author = David J. Triggle | title = Dictionary of pharmacological agents | publisher = Chapman & Hall | location = London | year = 1997 | pages = | isbn = 0-412-46630-9 | oclc = | doi = | accessdate = }}</ref> It has improved [[lipid]] [[solubility]] relative to thiamine and is not rate-limited by dependency on intestinal [[membrane transport protein|transporter]]s for absorption, hence the reasoning for its development.<ref name="pmid5551161">{{cite journal |vauthors=Thomson AD, Frank O, Baker H, Leevy CM | title = Thiamine propyl disulfide: absorption and utilization | journal = Annals of Internal Medicine | volume = 74 | issue = 4 | pages = 529–34 |date=April 1971 | pmid = 5551161 | doi = 10.7326/0003-4819-74-4-529| url = }}</ref><ref name="pmid978282">{{cite journal |vauthors=Baker H, Frank O | title = Absorption, utilization and clinical effectiveness of allithiamines compared to water-soluble thiamines | journal = Journal of Nutritional Science and Vitaminology | volume = 22 SUPPL | issue = | pages = 63–8 |date=August 1976 | pmid = 978282 | doi = | url = }}</ref> It is also a potential treatment for [[HTLV]], since it has been shown to reduce viral load and symptoms.<ref>[http://www.sciencedaily.com/releases/2013/08/130815084757.htm Nervous System Disease: A New Outlet for an Old Drug?]</ref>

==See also==
* [[Vitamin B1 analogue|Vitamin B<sub>1</sub> analogue]]

==References==
{{Reflist|2}}

{{Vitamins}}

[[Category:Formamides]]
[[Category:Amines]]
[[Category:Organic disulfides]]
[[Category:Pyrimidines]]
[[Category:Thiamine]]


{{amine-stub}}